Table 5
Benefit of SK in patients with a window period >6 h
Antibody levels
‘Benefit’ with SK
No
Yes
≤320
16 (45.71%)
17 (89.47%)
320+
19 (54.29%)
2 (10.53%)
Total
35
19
p=0.002.
SK, streptokinase.